136 related articles for article (PubMed ID: 1676932)
1. Parkinson's disease monotherapy with controlled-release MK-458 (PHNO): double-blind study and comparison to carbidopa/levodopa.
Ahlskog JE; Muenter MD; Bailey PA; Miller PM
Clin Neuropharmacol; 1991 Jun; 14(3):214-27. PubMed ID: 1676932
[TBL] [Abstract][Full Text] [Related]
2. MK 458, a selective and potent D2 receptor agonist in advanced Parkinson's disease.
Lieberman A; Chin L; Baumann G
Clin Neuropharmacol; 1988 Jun; 11(3):191-200. PubMed ID: 2900065
[TBL] [Abstract][Full Text] [Related]
3. Sustained-release (+)-PHNO [MK-458 (HPMC)] in the treatment of Parkinson's disease: evidence for tolerance to a selective D2-receptor agonist administered as a long-acting formulation.
Cedarbaum JM; Clark M; Toy LH; Green-Parsons A
Mov Disord; 1990; 5(4):298-303. PubMed ID: 1979657
[TBL] [Abstract][Full Text] [Related]
4. Effect of MK-458 (HPMC) in Parkinson's disease previously untreated with dopaminergic drugs. A double-blind, placebo-controlled multicenter study.
Koller WC; Block GA; Ahlskog JE; Ahrens S; Cedarbaum JM; Cyhan G; Goetz CG; LeWitt PA; Liss C; McLean L
Clin Neuropharmacol; 1991 Aug; 14(4):322-9. PubMed ID: 1913699
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of (+)-4-propyl-9-hydroxynaphthoxazine as adjunctive therapy in Parkinson's disease.
Weiner WJ; Factor SA; Sanchez-Ramos JR
J Neurol Neurosurg Psychiatry; 1989 Jun; 52(6):732-5. PubMed ID: 2746265
[TBL] [Abstract][Full Text] [Related]
6. Dopamine agonist treatment of fluctuating parkinsonism. D-2 (controlled-release MK-458) vs combined D-1 and D-2 (pergolide).
Ahlskog JE; Muenter MD; Bailey PA; Stevens PM
Arch Neurol; 1992 May; 49(5):560-8. PubMed ID: 1580821
[TBL] [Abstract][Full Text] [Related]
7. Antiparkinsonian activity of a single oral dose of PHNO.
Grandas F; Quinn N; Critchley P; Rohan A; Marsden CD; Stahl SM
Mov Disord; 1987; 2(1):47-51. PubMed ID: 2904120
[TBL] [Abstract][Full Text] [Related]
8. Levodopa and the progression of Parkinson's disease.
Fahn S; Oakes D; Shoulson I; Kieburtz K; Rudolph A; Lang A; Olanow CW; Tanner C; Marek K;
N Engl J Med; 2004 Dec; 351(24):2498-508. PubMed ID: 15590952
[TBL] [Abstract][Full Text] [Related]
9. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial.
Hauser RA; Hsu A; Kell S; Espay AJ; Sethi K; Stacy M; Ondo W; O'Connell M; Gupta S;
Lancet Neurol; 2013 Apr; 12(4):346-56. PubMed ID: 23485610
[TBL] [Abstract][Full Text] [Related]
10. PHNO [(+)-4-propyl-9-hydroxynaphthoxazine]: a new and effective anti-Parkinson's disease agent.
Muenter MD; Ahlskog JE; Bell G; McManis P
Neurology; 1988 Oct; 38(10):1541-5. PubMed ID: 2901697
[TBL] [Abstract][Full Text] [Related]
11. Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson's disease patients with fluctuating responses to levodopa/carbidopa.
Lieberman A; Imke S; Muenter M; Wheeler K; Ahlskog JE; Matsumoto JY; Maraganore DM; Wright KF; Schoenfelder J
Neurology; 1993 Oct; 43(10):1981-4. PubMed ID: 8105422
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety and maintenance of efficacy of levodopa-carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced Parkinson's disease patients.
Slevin JT; Fernandez HH; Zadikoff C; Hall C; Eaton S; Dubow J; Chatamra K; Benesh J
J Parkinsons Dis; 2015; 5(1):165-74. PubMed ID: 25588353
[TBL] [Abstract][Full Text] [Related]
13. [The effect of controlled release of DOPA and carbidopa on clinical response and plasma pharmacokinetics of DOPA in parkinsonian patients].
García de Yébenes J; Mateo D; Pino MA; Cordero M; Pastor M; Chacón J; Morales B; Sánchez V; Mena MA; Giménez Roldán S
Neurologia; 1997 Apr; 12(4):145-56. PubMed ID: 9235023
[TBL] [Abstract][Full Text] [Related]
14. Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's disease.
Tetrud J; Nausieda P; Kreitzman D; Liang GS; Nieves A; Duker AP; Hauser RA; Farbman ES; Ellenbogen A; Hsu A; Kell S; Khanna S; Rubens R; Gupta S
J Neurol Sci; 2017 Feb; 373():116-123. PubMed ID: 28131167
[TBL] [Abstract][Full Text] [Related]
15. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
Parkinson Study Group
JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
[TBL] [Abstract][Full Text] [Related]
16. Controlled-release levodopa/carbidopa. I. Sinemet CR3 treatment of response fluctuations in Parkinson's disease.
Cedarbaum JM; Breck L; Kutt H; McDowell FH
Neurology; 1987 Feb; 37(2):233-41. PubMed ID: 3808304
[TBL] [Abstract][Full Text] [Related]
17. Controlled-release carbidopa-levodopa (Sinemet) in combination with standard Sinemet in advanced Parkinson's disease.
Mark MH; Sage JI
Ann Clin Lab Sci; 1989; 19(2):101-6. PubMed ID: 2665626
[TBL] [Abstract][Full Text] [Related]
18. Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's disease.
Addy C; Assaid C; Hreniuk D; Stroh M; Xu Y; Herring WJ; Ellenbogen A; Jinnah HA; Kirby L; Leibowitz MT; Stewart RM; Tarsy D; Tetrud J; Stoch SA; Gottesdiener K; Wagner J
J Clin Pharmacol; 2009 Jul; 49(7):856-64. PubMed ID: 19491335
[TBL] [Abstract][Full Text] [Related]
19. Long-acting carbidopa-levodopa in the management of moderate and advanced Parkinson's disease.
Hutton JT; Morris JL
Neurology; 1992 Jan; 42(1 Suppl 1):51-6; discussion 57-60. PubMed ID: 1549202
[TBL] [Abstract][Full Text] [Related]
20. Treatment of chronic Parkinson's disease with controlled-release carbidopa/levodopa.
Hutton JT; Morris JL; Román GC; Imke SC; Elias JW
Arch Neurol; 1988 Aug; 45(8):861-4. PubMed ID: 3395259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
